Strategic Projects

Strategic projects involve consortia made up of companies and SINAI organisations that, due to their focus or technological development, are of key importance to Navarre. These projects are aligned with the sectors identified in Navarre’s Smart Specialisation Strategy. (S4).

ADItech participates in these projects as a partner with the aim of including gender considerations in the research content, to achieve scientific and technological excellence and obtain more beneficial results for society as a whole.

To carry out this work, ADItech collaborates with world-renowned experts to incorporate a gender perspective across various fields of knowledge. These experts guide and advise the teams in the development of the project.

There is also a Gender Consideration Guide that follows internationally recognised guidelines in this area: literature review, research hypothesis, methodology, ethics, etc.

The projects are financed by the Government of Navarre, as part of the calls for grants for Strategic R&D Projects.

If you want to know more, contact ADItech. The calls and projects in which ADItech participates and has participated are detailed below:

IRATI

Interacciones inflamatorias entre cáncer de vías Respiratorias y enfermedad cardiovascular: Nuevas herramientas diagnósticas y Terapias Inmunomoduladoras

IRATI propone valorar la afectación cardiaca y la evolución tumoral en pacientes con cáncer de pulmón tratados con inmunoterapia, analizando también las diferencias entre hombres y mujeres, ya que existen mecanismos diferenciales entre sexos en el desarrollo de la afectación cardiovascular y en la respuesta a la inmunoterapia. Para mejorar el diagnóstico precoz y la monitorización de los pacientes se plantea el desarrollo de distintas herramientas: Una aplicación basada en inteligencia artificial (IA) para el análisis optimizado y automatizado de las pruebas de imagen cardiacas y pulmonares, que reduzca el tiempo y el coste asociado a su análisis y mejore su sensibilidad para identificar patrones tempranos de daño; Biomarcadores innovadores basados en compuestos volátiles en exhalado respiratorio; Biomarcadores sanguíneos derivados de un estudio de proteómica dirigida; Una plataforma basada en IA que integre los datos clínicos y moleculares, para mejorar la estratificación de riesgo y seguimiento de los pacientes, avanzando hacia la implementación de estrategias de medicina personalizada. Por otra parte, en los estudios experimentales se desarrollará un modelo murino innovador que combina la afectación cardiovascular (hipertensión, obesidad y afectación metabólica) con un modelo ortotópico de cáncer de pulmón. Este modelo (en machos y hembras ovariectomizadas) permitirá profundizar en el papel fisiopatológico de la inflamación en la interacción entre cáncer y daño cardiaco, identificar nuevas dianas terapéuticas y explorar la utilidad de terapias anti-inflamatorias para mejorar la eficacia del tratamiento y mitigar la cardiotoxicidad asociada. Globalmente, IRATI contribuirá a mejorar la práctica clínica al: evaluar el eje cáncer- enfermedad cardiovascular de manera integrada; mejorar la estratificación de pacientes con un perfil inmunológico y cardiovascular de alto riesgo; facilitar su monitorización para optimizar su seguimiento; y encontrar nuevas dianas terapéuticas con efectos beneficiosos en ambas patologies, que impidan las consecuencias negativas de su interacción. La integración estratégica de la dimensión de género (variable sexo y análisis de género) contribuirá a reducir el sesgo existente en este campo. Teniendo en cuenta el impacto sanitario (cronificación, hospitalizaciones, mortalidad…) y económico de ambas patologies, IRATI tendrá un impacto sanitario, social y económico relevante.

COORDINADOR Centro de Investigación Médica Aplicada (CIMA)

SOCIOS

Navarrabiomed FMS - Hospital Universitario de Navarra
Clínica Universidad de Navarra
ADItech
NNBi
Tairel Data
Eversens

BIOANCIENT

Alianza para la monitorización de la población centenaria y el desarrollo nano biotecnológico asociado al envejecimiento saludable en Navarra

El objetivo principal del proyecto es identificar tratamientos específicos que permitan desarrollar estrategias preventivas individualizadas para retrasar el envejecimiento y prevenir enfermedades crónicas asociadas, enfocándose en lograr un envejecimiento con mayor calidad de vida. Así como, diseñar y desarrollar métodos de diagnóstico innovadores que permitan la detección ágil y precoz de señales de senescencia, aportando innovaciones sustanciales en los ámbitos de terapia, diagnóstico y clínica.

COORDINADOR NAVARRABIOMED FMS - Hospital Universitario de Navarra

SOCIOS

Universidad Pública de Navarra
Centro de Investigación Médica Aplicada - CIMA
ADItech
TDN clínica traumatología y rehabilitación avanzada SLP
InsAIght Research Center S.L.
Tairel Data, S.L.
NUCAPS Nanotechnology S.L.

ALBA

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text css=""]

Identifying microproteins (MPs) to generate cancer vaccines. ALBA (Antigens for Liver and Breast Anticancer Vaccines).

Research to advance the treatment of liver and breast cancers with immunotherapies based on neoantigens, such as vaccines derived from tumour mutations, with gender taken into consideration throughout the research. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR FIMA-CIMA

SOCIOS

FUNDACIÓN MIGUEL SERVET – NAVARRABIOMED
HUN
CUN-UNAV
NNBi
NUCAPS
NASERTIC
ADItech

PLENTYFOOD

Development of healthy and sustainable foods with intake regulatory capacity

The project focuses on the development of healthy and sustainable foods that provide the capacity to regulate satiety, aimed at vulnerable population groups with malnutrition by default or due to excessive intake. It seeks to optimise energy and nutrient intake by creating a range of prototype foods that form part of healthy diets for the treatment and prevention of malnutrition and obesity, with gender taken into consideration throughout the research. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR TUTTIPASTA

SOCIOS

IAN
IBERFRUTA
VLVN
INGREDALIA
NUCAPS
AN
DOMUSVI
CNTA
UNAV
ADItech

TEGER

Technology platform to identify, develop and deliver gene therapy vectors to combat genetic kidney diseases: Treatment of autosomal dominant polycystic disease type II

TEGER refers to the search for innovative solutions for hereditary kidney diseases in Navarre through the development of advanced therapies based on mass sequencing and focused on the mutations that cause polycystic kidney disease, with gender taken into consideration throughout the research. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR FIMA-CIMA

SOCIOS

VIVET THERAPEUTICS
VIDORRETA DESIGN
CUN-UNAV
FUNDACIÓN MIGUEL SERVET – NAVARRABIOMED – HUN
ADItech

SENSORFIT-4HEART

Development of a multiparametric platform for prescribing and remote monitoring of physical exercise in the treatment of heart failure with preserved ejection fraction (HFpEF)

Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome with an increasing incidence and a poor prognosis, already accounting for 50% of heart failure cases. This pathology is associated with ageing and cardiovascular risk factors (high blood pressure, diabetes, obesity...) It is more frequent in women than in men. Those who suffer from it often experience shortness of breath, debilitating fatigue, lower quality of life, frequent hospitalisations, and a high mortality rate. Despite its serious impact, most of the pharmacological treatments available for heart failure have not demonstrated a beneficial prognostic effect in patients with HFpEF. Several studies indicate that physical exercise has beneficial effects on heart failure, both on skeletal muscle and mitochondrial metabolism, as well as on the heart; effects that have been shown to be mediated by exerkines. In this context, SENSORFIT-4HEART proposes the implementation of a specific exercise programme in patients with HFpEF, as a potential catalyst for beneficial effects on cardiac function and remodelling, as well as on muscle bioenergetics, functional capacity and quality of life. The programme, which aims to be as personalised as possible, will be prescribed, modified and adjusted based on the results obtained from the monitoring of parameters that reflect functional capacity, physiological stress and circulating levels of exerkines in patients with HFpEF. The project plans to incorporate gender considerations into the content of every research phase. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR Fundación Miguel Servet – Navarrabiomed

SOCIOS

Fundación para la Investigación Médica Aplicada (FIMA)
ADItech
NAITEC
LORPELAND
540

ARNMUNE

Development of mRNA-based cancer immunotherapy

The treatment of people with cancer has progressed at a breakneck pace as a result of advances in cancer immunotherapy. However, not everyone responds to this treatment, and both the identification of those sensitive to immunotherapy, and the development of new, faster and more economical translation strategies, are necessary. To this end, ARNMUNE proposes the development of clinical trials based on preclinical research on mRNA drugs. Among the objectives to be pursued within the project framework, the following stand out: The project aims to validate new treatments in experimental models while optimising the use of infrastructures. It will advance research and development of new immunotherapeutic agents to bring them to clinical research under solid intellectual property protection. The project will also establish biomarkers to identify patient subgroups who do not respond to current onco-specific clinical strategies and could therefore benefit from these new immunotherapy approaches. The gender perspective will be integrated throughout the entire research process. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR CIMA

SOCIOS

Universidad de Navarra
Leadartis
InnoUp
Fundación Miguel Servet – Navarrabiomed
ADItech

WEB Web oficial del proyecto

NAGEN-DATA

The ecosystem of use and reuse of genomic data from the Genoma Navarra project

The NAGEN Programme is a strategic initiative to implement genome analysis in the clinical practice of the Servicio Navarro de Salud-Osasunbidea (Navarre health service). The fundamental objective of NAGEN DATA is to create an ecosystem of infrastructure, analytical tools, regulatory frameworks, and communication and patient participation mechanisms. Its purpose is to enable the reuse of genomic data within a sustainable, circular economy framework, in order to enhance health research and promote healthcare, positioning the Autonomous Community of Navarre as a leader in optimising genomic resources. NAGEN-DATA will build upon federated data sharing models to create a secure infrastructure that is compatible and aligned with ethical and regulatory frameworks from the design stage. Through specific bioinformatics tools developed collaboratively by the research team within the IMPaCT-Data programme, along with previous developments from the NAGEN programme, this infrastructure will enable remote interrogation of genomic and clinical data without reference to specific samples or patients, thereby mitigating privacy risks. It will also allow connection with similar national and international repositories within a federated, secure, and equitable environment. Specifically, the infrastructure will host tools that enable reanalysis of genomes included in the ecosystem for healthcare purposes by the Navarre Health Service through file reidentification. It is designed from the outset with key compatibility elements that will allow integration with other biomedical data ecosystems, medical records, and digital medical imaging to fully develop personalised medicine in the community. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR Fundación Miguel Servet Navarrabiomed (FMS-NB)

SOCIOS

NASERTIC
HUN
UPNA (Departamento de Derecho Civil)
Ysium Medical
Data Value Management
ADItech

INNOLFACT 2.0

Combinación de Inteligencia Artificial y Reposicionamiento de Fármacos en Medicina de Precisión Olfatoria

En el proyecto INNOLFACT se aplicaron enfoques disruptivos y exitosos en la caracterización del eje olfato-sistema inmune-cerebro. Generados tanto los datos clínicos, inmunológicos y olfativos asociados a más de 300 pacientes incluidos en esta fase así como las huellas ómicas olfativas asociadas a procesos de neurodegeneración, como la Enfermedad de Párkinson y Alzheimer. INNOLFACT 2.0 recurrirá a la inteligencia artificial/machine learning para generar: herramientas y algoritmos innovadores para clasificar y diagnosticar de manera precoz las Enfermedades Neurodegenerativas, modelos predictivos de utilidad en entorno hospitalario y comunitario e identificar fármacos que reviertan las huellas ómicas asociadas a neurodegeneración y que tengan capacidad de interferir con su progresión en mujeres y hombres, destacando sus diferencias si las hubiere e incorporando a las soluciones la perspectiva de género.

COORDINADOR Fundación Miguel Servet (FMS-NB-HUN)

SOCIOS

FIMA
CUN-UNAV
NNBi 2020
EVERSENS
ADItech

PITAGORAS

Plataforma para la Identificación de TCR específicos de AntíGenos tumOrales para inmunoteRApia de tumores Sólidos

La terapia con células TCR-T es una nueva modalidad de ACT muy atractiva para el tratamiento de los tumores sólidos. La gran ventaja de los TCR frente a los CAR en el tratamiento de estos tumores es la abundancia en ellos de antígenos tumorales (TA) intracelulares que solo pueden ser reconocidos por los TCR. En la actualidad hay dos abordajes de terapias con TCR: TCR compartidos, que reconocen “TA compartidos” por diferentes Pct/tumores; y TCR personalizados, que reconoce los “TA propios” del Pct. Los desafíos difieren para ambos abordajes: mientras que los TCR compartidos requieren soluciones que faciliten su implementación en la práctica clínica, los TCR personalizados necesitan de métodos sencillos para identificar TCR específicos de tumor y así abrirse paso en la medicina personalizada. En PITAGORAS afrontamos ambos desafíos.

COORDINADOR FIMA

SOCIOS

CUN
Navarrabiomed
HUN
Nasertic
IKAN Biotech
3P Biopharmaceuticals
ADItech

WEB Web oficial del proyecto

AI-ROB

Artificial intelligence and advanced robotics solutions in complex industrial environments AiRob seeks to improve working conditions for people with solutions where artificial intelligence, deep learning and robotics are brought together to solve complex problems in the manufacturing industry. In addition, the project is based in developing transversal and enabling ICT technologies for progress in industrial processes for handling information for decision making and using computational intelligence to improve working conditions.

COORDINADOR Aldakin Montajes Mantenimiento y Automatismos Eléctricos Navarra MANTENIMIENTO Y AUTOMATISMOS ELECTRICOS NAVARRA SL (MMAEN) del grupo ALDAKIN

SOCIOS

UDATA4
TedCas
Volkswagen Navarra
Técnicas Industriales en Decoración
Fundación Aspace
NAITEC
ADItech

LINTERNA

Leadership and innovation in cancer immunotherapy in Navarre (LINTERNA)

Treatment of oncology patients has advanced at breakneck speed as a consequence of advances in cancer immunotherapy. Thanks to the use of monoclonal antibodies that disinhibit certain brakes in the immune system, a significant portion of patients become long-term survivors. In Navarre, we have experts in several areas including immunotherapy and preclinical research and clinical practice (clinical trials), as well as pharmaceutical companies that are leaders in stimulating the immune system against cancer.

The LINTERNA project emerged to unify and consolidate the synergetic collaboration between those groups in order to (i) improve immunotherapy treatments using genome techniques, (ii) validate new treatments in experimental models optimising the use of infrastructures, (iii) and promote participation in and carrying out clinical trials for cancer immunotherapy in hospitals in Navarre.

COORDINADOR CIMA – Universidad de Navarra

SOCIOS

Clínica Universidad de Navarra (CUN)
Mediobiofarma
Complejo Hospitalario de Navarra (CHN)
Navarrabiomed
ADItech

EMOTIONALFILMS

A disruptive new audiovisual format that changes depending on the viewer's emotions in a dynamic and transparent way

The goal of the Emotional Films project is to develop a new concept for an audiovisual format based on the idea of providing personalised content in a dynamic and transparent way to each viewer depending on the emotions they show in response to different events and stimuli that occur throughout the content. An artificial intelligence (AI) that can detect and extract emotional information is being developed to do that. Emotional Films is striving for viewers to be totally immersed in the content without needing to have them interact directly with the content.

See the Emotional Films application

COORDINADOR KAKURU

SOCIOS

Universidad Pública de Navarra
ADItech
Universidad de Navarra
CREENA

INNOLFACT

Implementation of precision olfactory medicine and developing nasal immunomodulator therapies in ageing and neurodegeneration

Research done previously in Navarre showed a direct association between the sense of smell and the immune system and its impact on cognitive and motor functions. In an ageing society, we need disruptive approaches that generate innovative tools for detecting and diagnosing neurodegenerative illnesses early. The goal of the INNOLFACT project is to implement the practice of precision olfactory medicine (POM) and develop nasal therapies that modulate the immune system in the brain.

INNOLFACT intends to provide a range of olfactory analyses that offer personalised management of ageing and the associated neurodegenerative diseases in terms of early diagnosis and slowing clinical progression.

COORDINADOR Fundación Miguel Servet-Navarrabiomed

SOCIOS

Hospital Universitario de Navarra
Centro de Investigación Médica Aplicada (CIMA)
Clínica Universidad de Navarra (CUN)
Ojer Pharma
ADItech

NUTRI+

AVANZADO EN LA NUTRICIÓN DE PERSONAS CON NECESIDADES ESPECIALES. El objetivo del proyecto Nutri+ es hacer más atractiva y saludable la dieta de determinados grupos de población especialmente vulnerables con necesidades específicas. Para conseguirlo, en este proyecto se investigan y desarrollan ingredientes y alimentos con texturas adaptadas a problemas de masticación y deglución. Productos que además son visualmente atractivos, con un perfil funcional saludable que permiten diseñar dietas equilibradas. Así se consigue prevenir patologías en estos grupos de población y mejorar su calidad de vida. Gracias a la colaboración de ADItech en este proyecto, también se ha incorporado la dimensión de género teniendo en cuenta las necesidades específicas de ambos sexos lo cual contribuye a alcanzar mejor el objetivo del proyecto.

COORDINADOR DOMUSVI

SOCIOS

ADACEN
Tutti Pasta
IAN
FRISA
COCUUS
Centro Nacional de Tecnología y Seguridad Alimentaria (CNTA)
Universidad de Navarra
Hospital Universitario de Navarra
ADItech

Strategic Projects

ADItech collaborated with the government of Navarre on publicising the strategic projects financed by the government of Navarre in the 2018-2020 call for proposals. The Boletus and Aurbelec projects are centred on designing long range electric vehicles and advanced technology. Aralar and e-Hiera are projects seeking to improve the use and storage of renewable energy. And, lastly, in the area of health, the Nagen and Diana projects are researching complete DNA sequencing and applications for it in advanced medicine.

PROMETEA

PRotección integral de afecciOnes inMunocirculatorias En la Tercera Edad (Comprehensive Protection of Immunocirculatory Conditions in the Elderly)

In Europe, it is estimated that more than 10 million people suffer from pressure ulcers (PU); a condition with an incidence in the adult population of between 5% and 12%, reaching 20% in geriatric patients with acute and/or chronic diseases. The environment of these wounds and their progression — particularly exacerbated in bedridden individuals due to body pressure and friction with clothing and bedding — means that new technologies and antimicrobial textiles play a significant role in improving therapeutic approaches and ensuring a better quality of life. In this regard, the general objective of the PROMETEA project is to achieve combined treatments that enable the regeneration of epithelia while controlling infection and inflammation processes. This will be accomplished through the prevention of infections and the stimulation of the defences of affected individuals. Thanks to the collaboration of ADItech in this project, gender has also been considered, taking into account the specific needs of both sexes, which helps achieve the project's objective more effectively. This work has been made possible thanks to the collaboration of  Olaya Fernández Guerrero and Remedios Álvarez Terán of the University of La Rioja. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR Biosasun

SOCIOS

Asociación Allotarra de Agricultura y Ganadería Ecológica
DOMUSVI
EZTITSU
Granja escuela Ultzama
TECNAN
Centro Tecnológico Lurederra
Universidad Pública de Navarra (UPNA)
Centro Nacional de Tecnología y Seguridad Alimentaria (CNTA)
ADItech

NanoRC

RNA nanotransporter-based therapy for cancer treatment

Currently, cancer is the second leading cause of death in developed Western countries, after cardiovascular disease. Despite the remarkable advances in the knowledge of the biological mechanisms involved and new therapeutic approaches, the search for treatments with an adequate safety/efficacy balance continues to be one of the main priorities. The NanoRC project focuses on personalised cancer treatment, modelled on multiple myeloma (MM). To achieve this, personalized specific siRNA will be generated based on the genomic and transcriptomic information of patients. These siRNA will be administered using nanoparticles. Nanotransporters will protect RNA from degradation, specifically target it to tumour cells, and allow for internalisation of the RNA. Once inside the tumour cells, the RNA will specifically bind to its target, exerting the desired therapeutic effect. Thanks to the collaboration of ADItech in this project, gender has also been considered, taking into account the specific needs of both sexes, which helps achieve the project's objective more effectively. This work has been made possible thanks to the collaboration of Morteza Mahmoudi of Michigan State University. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR Universidad de Navarra / Clínica Universidad de Navarra (CUN)

SOCIOS

Centro de Investigación Médica Aplicada (CIMA)
Fundación Miguel Servet-Navarrabiomed
IKAN Biotech
ADItech

BIOHEART

Bioingeniería avanzada para el desarrollo del tejido cardiaco y su aplicación al estudio y detección de cardiotoxicidad

This project tackles the challenge of advancing 3D printing technology and biomaterials to enable the development of human cardiac tissue in the laboratory, ranging from mini-hearts to complete organs. Additionally, it aims to establish them as an effective and innovative platform for the early detection of cardiotoxicity. The objective is to position Navarre as an innovation node in the development of biofabrication technology and the production of bio-artificial human heart tissues. Additionally, it aims to utilize these tissues for industrial and (pre-) clinical testing of cardiotoxicity. The consortium behind this project will work on the development of technological and biomedical tools for the design, development, manufacture and implementation of cardiotoxicity testing platforms, with different capacities. It will also proactively evaluate their valorisation. This will be based on state-of-the-art technology: from human iPSC stem cells, multifunctional 3D printing and biomaterials, to the in vivo generation of humanised hearts by blastocyst complementation. Thanks to the collaboration of ADItech in this project, gender has also been considered, taking into account the specific needs of both sexes, which helps achieve the project's objective more effectively. This work has been made possible thanks to the collaboration of Lourdes Chacon-Alberty of the Texas Heart Institute. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR Centro de Investigación Médica Aplicada (CIMA)

SOCIOS

Fundación Miguel Servet-Navarrabiomed
AIN
Los Alecos
Nadetech Innovations
Hospital Universitario de Navarra (HUN)
Universidad de Navarra / Clínica Universidad de Navarra (CUN)
ADItech

WEB Web oficial del proyecto

BLANCA

BLANCA (Breast Long non coding ANti-Cancer Antigens) Using genomic data to develop a cancer vaccine

Using genomic data to develop a cancer vaccine. The fundamental objective of the BLANCA project is to develop a vaccine for the treatment of breast cancer. To this end, massive data from cancer patients will be obtained and analysed, looking for non-coding RNA that is expressed in the tumour and can generate immunogenic micropeptides. This is a unique opportunity to establish cutting-edge technology in genomics, bioinformatics, molecular biology, and chemistry. It will enable the creation of a technological platform, positioning Navarre as a leader in cancer treatment and RNA vaccine production for various diseases and future pandemics. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR Fundación para la Investigación Médica Aplicada (FIMA)

SOCIOS

Clínica Universidad de Navarra (CUN)
Fundación Miguel Servet-Navarrabiomed
Hospital Universitario de Navarra
Bionanoplus
Saray
ADItech

WEB Web oficial del proyecto

μBIOMICS

Applications of multi-omic microbiota study to the development of innovative biotechnological solutions in health

Recent studies indicate that microbial communities play a critical role in human health. These microorganisms, collectively referred to as microbiota, participate both in the pathophysiology of different diseases and in the response of patients to pharmacological treatments. MicroBiomics (μBiomics) proposes the design, development, and implementation of a multi-omic platform and a set of bioinformatics tools. This will allow for the characterisation, at an unprecedented level of detail and in a completely novel way, of the role of the microbiota in various pathological processes, including digestive, autoimmune, and oncological conditions. The final objective of the project is to identify bacterial communities and their activity for the design of therapeutic strategies based on biotechnology. Thanks to the collaboration of ADItech on this project, gender has also been considered, taking into account the specific needs of both sexes, which helps achieve the project's objective more effectively. This work has been made possible thanks to the collaboration of Irene Miguel-Aliaga, Imperial College London and the Francis Crick Institute. [/vc_column_text][/vc_column][/vc_row]

COORDINADOR Fundación para la Investigación Médica Aplicada (FIMA)

SOCIOS

Fundación Miguel Servet-Navarrabiomed
Clínica Universidad de Navarra (CUN)
Hospital Universitario de Navarra
Fundación Miguel Servet (FMS)
Universidad de Navarra (CIMA LAB Diagnostics, Centro de Investigación Nutrición)
NUCAPS
Centro Nacional de Tecnología y Seguridad Alimentaria (CNTA)
ADItech

WEB Web oficial del proyecto